INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09806103	
Art Unit		2001-03-28	
		hiro Hayashi	
		2618	
		n J. Fox	
		33388	

				U.S	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Pat of cited Doc	tentee or Applicant ument	Releva	Columns,Lines w int Passages or R s Appear	
	1	5584054		1996-12-10	Tyneski et al.				
	2	5638455		1997-06-10	Peiker				
	3	5832080		1998-11-03	Beutler et al				
	4	5841849		1998-11-24	Macor				
If you wis	h to a	dd additional U.S. Pater	nt citatio	n information	please click the	Add button.		Add	
			U.S.P	ATENT APPL	ICATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	name of Patentee or Applicant		Releva	Columns,Lines w int Passages or R s Appear	
	1								
If you wisl	h to a	l dd additional U.S. Publi	shed Ap	plication citati	on information	please click the Ad	d button	Add	
				FOREIGN PA	TENT DOCUM	MENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Publication Date	Name of Patente Applicant of cited Document	or v	Pages,Columns,Li vhere Relevant Passages or Relev Figures Appear	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09806103
Filing Date		2001-03-28
First Named Inventor	Takai	hiro Hayashi
Art Unit		2618
Examiner Name Bryan		ı J. Fox
Attornou Docket Numb	ne.	22200

	1	0 851 643	EP	A2	1998-07-01			V		
	2	98/19226	wo		2006-08-28			V		
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
	NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*	Cite No							T5		
	1									
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE										
Examiner Signature Date Considered										
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

1 See fand, Codes of USPTO Platent Documents at <u>www.USPTO.0007</u> or MFPEP 010.4. * Enter office in that issued the document, by the two-letter code (WIPO Standard STI3.). **Port planesee parted consents, the endication of the paper of being rings of the director consent one seed in the first planes of the paper of the rings of the director consents by the specifies synthos as indicated on the document under WIPO Standard STI.16 if possible, **Applicant is to place a check mark here if the paper of the region of the document by the specifies synthos as indicated on the document under WIPO Standard STI.16 if possible, **Applicant is to place a check mark here if the paper of the paper of the page of the pag

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date First Named Inventor Takat Art Unit			09806103	
			2001-03-28	
		Takai	hiro Hayashi	
			2618	
	Examiner Name	Bryan	n J. Fox	
Attorney Docket Number		er	33388	

27676

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make th	he appropriate selection(s):
---------------	----------	---------------------	------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 27 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement less known to a not individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement less of 7.5FE 197(c).

See attached certification statement.

Jeffrey J. Sonko.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

form of the signature.						
	Signature	/Jeffrey J. Sopko/	Date (YYYY-MM-DD)	2006-08-29		

Registration Number

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is not lie and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, P. 0. Box 1450, Alexandria, V.3.231-1450, D. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan Koffice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested in the contraction of the contraction of the patient o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such Adeckouse shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record vals filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to public insepections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.